Xiangjin Xu

699 total citations
32 papers, 529 citations indexed

About

Xiangjin Xu is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Physiology. According to data from OpenAlex, Xiangjin Xu has authored 32 papers receiving a total of 529 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Molecular Biology and 6 papers in Physiology. Recurrent topics in Xiangjin Xu's work include Metabolism, Diabetes, and Cancer (14 papers), Diabetes Treatment and Management (12 papers) and Diabetes Management and Research (10 papers). Xiangjin Xu is often cited by papers focused on Metabolism, Diabetes, and Cancer (14 papers), Diabetes Treatment and Management (12 papers) and Diabetes Management and Research (10 papers). Xiangjin Xu collaborates with scholars based in China, Denmark and Switzerland. Xiangjin Xu's co-authors include Lu Lin, Pin Chen, Wen Guo, Xiangqi Chen, Wenqing Wang, Qin Liao, Daohua Shi, Wei Zheng, Yanqiao Wang and Wenyu Chen and has published in prestigious journals such as PLoS ONE, Diabetes and Biochemical and Biophysical Research Communications.

In The Last Decade

Xiangjin Xu

32 papers receiving 519 citations

Peers

Countries citing papers authored by Xiangjin Xu

Since Specialization

Citations

This map shows the geographic impact of Xiangjin Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiangjin Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiangjin Xu more than expected).

Fields of papers citing papers by Xiangjin Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiangjin Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiangjin Xu. The network helps show where Xiangjin Xu may publish in the future.

Co-authorship network of co-authors of Xiangjin Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiangjin Xu. A scholar is included among the top collaborators of Xiangjin Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiangjin Xu. Xiangjin Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Upregulation of Metrnl improves diabetic kidney disease by inhibiting the TGF-β1/Smads signaling pathway: A potential therapeutic target	PLoS ONE	Lin Lu, Xiaoling Liu et al.	2
2	Scanning Electron Microscopic Observation on Chalkiness of Rice Mutant OsLHT1 Grains	Journal of Agricultural Science	Bo Peng, Juan Peng et al.	1
3	Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study	Journal of Diabetes Research	Siyao He, Xin Qian et al.	8
4	PTPN14 deficiency alleviates podocyte injury through suppressing inflammation and fibrosis by targeting TRIP6 in diabetic nephropathy	Biochemical and Biophysical Research Communications	Meng Zhao, Jinghui Li et al.	8
5	Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial	Diabetes Research and Clinical Practice	Wen Guo, Lu Lin et al.	84
6	Insulin delivery with a needle-free insulin injector versus a conventional insulin pen in Chinese patients with type 2 diabetes mellitus: A 16-week, multicenter, randomized clinical trial (the FREE study)	EClinicalMedicine	Linong Ji, Leili Gao et al.	10
7	Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats	Tissue and Cell	Xiangjin Xu, Wenqing Wang et al.	37
8	Efficacy and safety of linagliptin as add‐on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled trial	Diabetes Obesity and Metabolism	Wenying Yang, Xiangjin Xu et al.	7
9	Dietary pattern in overweight and obese patients with type 2 diabetes mellitus		Xiangjin Xu et al.	1
10	Study Protocol for a Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of a Needle-Free Insulin Injector and a Conventional Insulin Pen in Controlling Blood Glucose Concentrations in Chinese Patients with Type 2 Diabetes Mellitus (The FREE Study)	Advances in Therapy	Linong Ji, Yangang Wang et al.	3
11	Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study	Diabetes Research and Clinical Practice	Xiangjin Xu, Lu Lin et al.	47
12	Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial	Diabetes Obesity and Metabolism	Wenying Yang, Jianhua Ma et al.	18
13	Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model	Diabetes Research and Clinical Practice	Pin Chen, Xiangjin Xu et al.	39
14	Protective effects of combining human umbilical cord mesenchymal stem cells and glucagon like peptide-1 receptor agonist on the islet inflammatory injury in rat model of type 2 diabetes mellitus	Zhonghua neifenmi daixie zazhi	Chen Pin, Shan Huang et al.	2
15	Effect of liraglutide combined with bone marrow mesenchymal stem cells on glucose metabolism in experimental type 1 diabetic rats by regulating gastrointestinal hormones	Zhonghua neifenmi daixie zazhi	Pin Chen, Xiangjin Xu et al.	1
16	Effect of glucagon like peptide-1 receptor agonist combined human umbilical cord mesenchymal stem cells on the glucose metabolism and the islet β cell function in type 2 diabetic SD rats		Chen Pin, Xiangjin Xu et al.	1
17	Efficacy and safety of liraglutide compared with insulin glargine in patients with type 2 diabetes mellitus inadequately controlled with metformin	Zhonghua neifenmi daixie zazhi	Wen Guo, Fang Li et al.	1
18	Effects of liraglutide on the differentiation of human bone marrow mesenchymal stem cells into insulin producing cells	Zhonghua neifenmi daixie zazhi	Chen Pin, Huiling Wang et al.	1
19	Effect of pioglitazone on diabetic nephropathy and expression of HIF-1α and VEGF in the renal tissues of type 2 diabetic rats	Diabetes Research and Clinical Practice	Xiangjin Xu, Yanqiao Wang et al.	30
20	Antiproliferation of cardamonin is involved in mTOR on aortic smooth muscle cells in high fructose-induced insulin resistance rats	European Journal of Pharmacology	Qin Liao, Daohua Shi et al.	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact